Blatt, Eliot B. http://orcid.org/0000-0002-9515-6547
Parra, Karla
Neeb, Antje
Buroni, Lorenzo
Bogdan, Denisa
Yuan, Wei
Gao, Yunpeng
Gilbreath, Collin
Paschalis, Alec
Carreira, Suzanne http://orcid.org/0000-0002-5077-5379
DeBerardinis, Ralph J. http://orcid.org/0000-0002-2705-7432
Mani, Ram S. http://orcid.org/0000-0003-3552-7905
de Bono, Johann S.
Raj, Ganesh V. http://orcid.org/0000-0001-5098-6347
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-17-1-0674, W81XWH-19-1-0363, W81XWH-21-1-0687, W81XWH-21-1-0114)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F31CA243276-01A1, T32CA124334, R01CA245294)
Cancer Prevention and Research Institute of Texas (RP160157, RP190454)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 October 2022
Revised: 22 May 2023
Accepted: 13 June 2023
First Online: 24 June 2023
Competing interests
: GVR serves or has served in an advisory role to Bayer, Johnson and Johnson, Myovant, EtiraRx, Amgen, Pfizer and Astellas. He has or has had grant support from Bayer, EtiraRx and Johnson and Johnson. RJD is a founder and advisor for Atavistik Bioscience, and a scientific advisor for Agios Pharmaceuticals, Nirology Therapeutics, Droia Ventures, and Vida Ventures. JSdB has served on advisory boards and received fees from Amgen, Astra Zeneca, Astellas, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Harpoon, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, and Vertex Pharmaceuticals; is an employee of the Institute of Cancer Research (ICR), which have received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, and Vertex, and which has a commercial interest in ExternalRef removed, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income); was named as an inventor, with no financial interest for patent 8 822 438, submitted by Janssen that covers the use of ExternalRef removed with corticosteroids; has been the CI/PI of many industry-sponsored clinical trials; and is a National Institute for Health Research (NIHR) Senior Investigator. AN, LB, DB, WY, AP, SC, and JSdB are employees of the Institute of Cancer Research (ICR), which has commercial interest in abiraterone. No other authors have any potential conflicts of interest to disclose.